ACST Stock Overview
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Acasti Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.29 |
| 52 Week High | US$3.84 |
| 52 Week Low | US$1.72 |
| Beta | 1.62 |
| 1 Month Change | 22.39% |
| 3 Month Change | -3.17% |
| 1 Year Change | -3.74% |
| 3 Year Change | -87.30% |
| 5 Year Change | -93.47% |
| Change since IPO | -99.44% |
Recent News & Updates
We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
Apr 20
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Nov 14Recent updates
We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
Apr 20Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Nov 14We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
May 10Acasti Pharma GAAP EPS of -$0.10
Aug 11Acasti inks deal for Grace Therapeutics, shares surge
May 07Acasti Pharma issues clarification on trading activity
Dec 23Acasti Pharma EPS in-line
Nov 16Shareholder Returns
| ACST | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.2% | -0.2% | 1.6% |
| 1Y | -3.7% | 17.2% | 22.3% |
Return vs Industry: ACST underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: ACST underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| ACST volatility | |
|---|---|
| ACST Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ACST has not had significant price volatility in the past 3 months.
Volatility Over Time: ACST's weekly volatility has decreased from 11% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Prashant Kohli | www.acastipharma.com |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Acasti Pharma Inc. Fundamentals Summary
| ACST fundamental statistics | |
|---|---|
| Market cap | US$30.64m |
| Earnings (TTM) | -US$38.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs ACST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACST income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.77m |
| Earnings | -US$38.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACST perform over the long term?
See historical performance and comparison